Projected US Savings From Biosimilars, 2021–2025

Andrew W. Mulcahy, Christine Buttorff, Kenneth Finegold, Zeid El-Kilani, Jon F. Oliver, Stephen Murphy, Amber Jessup

ResearchPosted on rand.org Jan 26, 2022Published in: American Journal of Managed Care, Volume 28, No. 7 (July 2022)

Substituting biosimilar drugs for biologics could drive down the price of expensive medicines used to treat illnesses such as cancer and rheumatoid arthritis, with savings estimated to be $38.4 billion or 5.9% of projected total U.S. spending on biologics from 2021 to 2025.

Topics

Document Details

  • Availability: Non-RAND
  • Year: 2022
  • Pages: 27
  • Document Number: EP-68829

This publication is part of the RAND external publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.

RAND is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.